TAPO in first‐line osimertinib therapy and continuation of osimertinib

TAPO in first‐line osimertinib therapy and continuation of osimertinib

Abstract Background Osimertinib is associated with a relatively high frequency of drug‐induced interstitial lung disease (D‐ILD), and transient asymptomatic pulmonary opacities (TAPO) have been reported to occur during osimertinib administration. The frequency of TAPO during first‐line treatment and...

Full description

Bibliographic Details
Main Authors: Chihiro Mimura, Kazumi Kaneshiro, Shodai Fujimoto, Ryota Dokuni, Natsuhiko Iwamoto, Kanoko Matsumura, Yukihisa Hatakeyama, Yuko Kono, Motoko Tachihara
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Thoracic Cancer
Subjects:
interstitial lung disease
lung cancer
NSCLC
transient asymptomatic pulmonary opacity (TAPO)
Online Access:https://doi.org/10.1111/1759-7714.14782

Internet

https://doi.org/10.1111/1759-7714.14782

Similar Items